Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.

ABSTRACT:

Background

Genital psoriasis is highly prevalent among patients with psoriasis, is often stigmatized, causes pain and discomfort and negatively impacts quality of life. Apremilast is an oral phosphodiesterase 4 inhibitor approved for treating psoriasis and has demonstrated safety and efficacy in treating genital psoriasis, as seen in the primary 16-week DISCREET results.

Objectives

To assess the efficacy and safety of apremilast 30 mg twice daily in patients with moderate to severe genital psoriasis over the 32-week study duration.

Methods

DISCREET was a phase 3, multicentre, randomized, double-blind trial that evaluated apremilast 30 mg twice daily versus placebo in a 16-week placebo-controlled phase (randomization 1:1) followed by a 16-week apremilast extension phas

SUBMITTER: Merola JF 

PROVIDER: S-EPMC12843872 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature